Comparative Pharmacology
Head-to-head clinical analysis: BENAZEPRIL HYDROCHLORIDE versus MAVIK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENAZEPRIL HYDROCHLORIDE versus MAVIK.
BENAZEPRIL HYDROCHLORIDE vs MAVIK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benazepril is a prodrug that is hydrolyzed to benazeprilat, a competitive inhibitor of angiotensin-converting enzyme (ACE). This prevents conversion of angiotensin I to angiotensin II, resulting in decreased vasoconstriction, reduced aldosterone secretion, and lower blood pressure.
Angiotensin-converting enzyme (ACE) inhibitor; inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure and reduced cardiac workload.
Initial: 10 mg orally once daily. Titrate to 20-40 mg daily (as single dose or two divided doses). Maximum: 80 mg/day. Route: Oral.
Oral, 1-4 mg once daily for hypertension; 2-4 mg once daily for heart failure.
None Documented
None Documented
Benazeprilat terminal elimination half-life is approximately 10-11 hours in patients with normal renal function; clinically, steady-state is reached in 2-3 days. Half-life is prolonged in renal impairment (up to 22 hours in moderate to severe impairment), necessitating dose adjustment.
Trandolaprilat: terminal half-life ~24 hours (range 15–35 hours) for once-daily dosing; effective half-life ~6–10 hours at steady state.
Primarily renal (80-90% of absorbed dose excreted in urine, with approximately 20-30% as benazeprilat and the rest as inactive metabolites); biliary/fecal elimination accounts for the remainder (10-20%).
Renal: trandolapril ~33% (as trandolaprilat and metabolites), trandolaprilat ~33% (as unchanged and metabolites); biliary/fecal: ~66% of total radioactivity.
Category D/X
Category C
ACE Inhibitor
ACE Inhibitor